|
Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >
Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment
| Title: | Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment |
| Authors: | Saito, Yoshitaka Browse this author →KAKEN DB | | Takekuma, Yoh Browse this author →KAKEN DB | | Takeshita, Takashi Browse this author | | Oshino, Tomohiro Browse this author | | Sugawara, Mitsuru Browse this author →KAKEN DB |
| Keywords: | Taxane-associated acute pain syndrome | | Docetaxel | | Dexamethasone | | Dose-dependent | | Arthralgia | | Myalgia |
| Issue Date: | 3-Jun-2023 |
| Publisher: | Springer |
| Journal Title: | Supportive care in cancer |
| Volume: | 31 |
| Issue: | 6 |
| Start Page: | 372 |
| Publisher DOI: | 10.1007/s00520-023-07852-x |
| Abstract: | PurposeTaxane-associated acute pain syndrome (T-APS) is one of the most bothersome adverse effects caused by taxanes. We have previously reported the attenuating effect of dexamethasone (DEX) on T-APS and its risk factors under DEX prophylaxis. However, the appropriate DEX dosage administration remains unclear. Therefore, this study aimed to investigate whether DEX dose-dependently prevents T-APS in breast cancer patients.MethodsWe retrospectively evaluated patients with breast cancer who received docetaxel (75 mg/m(2))-containing chemotherapy without pegfilgrastim and regular non-steroidal anti-inflammatory drugs. The patients were divided into 4 mg/day and 8 mg/day DEX groups, with each DEX dosage on days 2-4 (n = 68 for each group). Primary endpoint was the comparison of all-grade T-APS incidence between the groups. Propensity score-matching was performed to adjust the baseline factors between the groups, and outcomes in the matched-population were also assessed.ResultsThe incidence of all-grade T-APS was 72.1% in 4 mg/day group and 48.5% in 8 mg/day group, which was significantly lowered by higher DEX dosage (P = 0.008). The severity of T-APS was also significantly reduced in 8 mg/day group (P = 0.02). These results were confirmed in the propensity score matching. Multivariate logistic analysis showed that higher DEX dosage was an independent T-APS preventive factor, whereas age < 55 years was a risk factor. Moreover, DEX-dosage-associated adverse effects similarly appeared in both groups.ConclusionOur study suggested that DEX dose-dependently prevents T-APS in breast cancer treatment. As understanding of the nature of T-APS and its appropriate management can significantly contribute to less onerous chemotherapy provision, further studies are required. |
| Rights: | This version of the article has been accepted for publication, after peer review and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s00520-023-07852-x |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/92585 |
| Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 齋藤 佳敬
|
